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the agents are no relevant substrates of nucleotide trans-
porters (MRP-4, MRP-5) expressed by skin cancer cells. Es-
sential kinases for nucleoside activation were detected, too, 
corresponding with the observed effects of nucleoside ana-
logues. Due to the rather high molecular weight and poor 
solubility, however, skin penetration should be poor and 
thus topical therapy may require carriers to improve the up-
take. This becomes feasible by lipidic and non-lipidic 
nanoparticles which can enhance the uptake of lipophilic 
agents up to 13-fold.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Due to aging and in particular because of an increased 
ultraviolet (UV) exposure in Western societies, the num-
ber of patients with actinic keratosis (carcinoma in situ) 
and cutaneous squamous cell carcinoma is increasing 
dramatically. UV-induced DNA damage results in C-to-
T transitions at bipyrimidine sites, e.g. in the p53 gene  [1] . 
Recently, the progression of actinic keratosis into squa-
mous cell carcinoma due to human papillomavirus 
(HPV) infection has been described (for a review, see 
Madkan et al.  [2] ). Patients with actinic keratosis proved 
to be more frequently positive for HPV (37 vs. 0%), and 
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 Abstract 
 Actinic keratosis and cutaneous squamous cell carcinoma 
are of increasing importance with aging and increased ultra-
violet light exposure in Western societies. Efficient and well-
tolerated therapy is still a matter of concern. As with tumours 
of other organs, new target sites and innovative drugs selec-
tively addressing them are widely looked for. Due to the rel-
evance for DNA synthesis and thus cell proliferation, human 
DNA polymerase   should be such a target, the more so as 
the three-dimensional structure of the active site has been 
proposed based on the application of molecular modelling 
methods and molecular dynamics simulations. The mod-
elled structure of the active site was used for docking nucle-
otide analogues in order to design selective inhibitors. Con-
sequently, well-fitting thymidine and guanosine analogues 
were synthesized and tested in vitro for their influence on 
normal and transformed human keratinocytes. In fact, the 
combination of modelling studies and in vitro tests allowed 
us to design antiproliferative and cytotoxic agents which are 
new drug candidates for the therapy of skin tumours, given 
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lesions removed by laser treatment more frequently re-
curred, if positive for herpesvirus  [3] . HPV positivity is 
particularly high (82%) in actinic keratosis lesions of im-
munosuppressed renal transplant recipients  [1] . HPV 
prevalence is also found increased in squamous cell car-
cinoma lesions of UV-irradiated SKH transgenic mice 
 [4] .
 Current therapy of actinic keratosis, however, can be 
painful and of insufficient efficacy as with 5-fluorouracil 
(5-FU) cream  [5] and photodynamic therapy using the 
UV sensitizer 5-aminolevulinic acid or its methyl ester 
prodrug  [6, 7] , or cure rates are not fully sufficient as with 
5-FU applied as a polymeric microsponge preparation 
 [5] . Carcinoma in situ therapy is not fully efficient either 
with diclofenac/hyaluronic acid  [8, 9] , which is reported 
to inhibit overexpressed cyclooxygenase-2 in these tu-
mours, or imiquimod, which stimulates the non-specific 
immune response by Toll-like receptor interaction  [10] .
 Therefore, alternative approaches like interference 
with DNA synthesis are under investigation. The human 
DNA polymerase   (pol   ) catalyzes the central step in 
DNA replication and therefore is an interesting target. In 
fact, the nucleoside pol   inhibitor gemcitabine is already 
used systemically for pancreas carcinoma, whereas the 
non-nucleosidic pol   and pol   inhibitor aphidicolin  [11] 
failed to be introduced into tumour therapy while it still 
remains the standard substance in experimental phar-
macology. Whereas cytarabine is active in leukaemia pre-
dominantly due to ribosyl reductase inhibition, 4  -thio-
FAC, similar to cytarabine and gemcitabine, potently in-
hibits pol   , and less so the repair enzyme pol    [12] . 
Aiming for actinic keratosis and squamous carcinoma 
therapy, selective non-nucleoside inhibitors of pol   , such 
as dehydroaltenusin  [13] , glycolipids from green tea and 
spinach  [13–15] and acyl catechins  [16, 17] , have been de-
scribed based on the results of preclinical testing strength-
ening the relevance of this target.
 Since nucleoside and nucleotide analogue polymerase 
inhibitors have revolutionized the treatment of infections 
by some herpesviruses (herpes simplex virus, cytomega-
lovirus), hepadna viruses inducing viral hepatitis, and 
the human immunodeficiency virus (HIV), DNA poly-
merase inhibitors of the nucleoside type might also be of 
highest interest in actinic keratosis treatment. None of 
these antiviral drugs, however, have been considered in 
this indication so far.
 To enable systematic access to the innovative target, 
we first modelled the structure of the active site of pol   . 
This enzyme belongs to the DNA polymerase B family, 
which includes several eukaryotic and archaeal polymer-
ases, as well as the viral adenovirus, herpes simplex virus 
type 1, RB69, T4 and T6 polymerases. Members of type B 
polymerase are of central importance in the accurate rep-
lication of the genetic material and despite diverse bio-
logical functions, the structural and chemical mecha-
nisms of base incorporation seem to be highly conserved. 
Crystallographic structures of DNA polymerases indi-
cate that these enzymes are composed of several func-
tionally distinct domains and subdomains. A general fea-
ture of polymerase structures, a large cleft comprised of 
3 subdomains, the ‘fingers’, the ‘palm’ and the ‘thumb’, 
can be characterized as a ‘right hand’ that is capable of 
holding DNA in its gaps  [18–20] . The palm subdomain at 
the bottom of the cleft contains the catalytic site, while 
the finger and thumb subdomains form the walls of the 
cleft. Three different conformations of RB69 polymerase 
have been observed in crystal structures: the apo state 
without DNA, the editing mode forming a binary com-
plex with DNA bound to the exonuclease site, and the 
replicating mode, a ternary complex with DNA and a de-
oxynucleotide triphosphate (dNTP) bound in the poly-
merase catalytic site. In the apo state and editing mode, 
the enzyme is in the ‘open’ form, showing a rotation of 
the fingers domain 60° away from the palm. In the ‘closed’ 
conformation, 1 arginine and 2 lysines of the fingers do-
main are involved in hydrogen bonding to the phosphate 
groups of the incoming dNTP. DNA synthesis is medi-
ated by transfer of a phosphoryl group from the incoming 
dNTP to the DNA 3  -OH, liberating pyrophosphate and 
forming a new DNA phosphoester bond. This reaction is 
catalyzed by a mechanism that involves 2 divalent metal 
ions, with the participation of 2 aspartic acid residues, 
which are structurally conserved among the different 
polymerase enzymes.
 Molecular modelling  [20] allowed us to identify selec-
tive nucleoside inhibitors  [21] . The potential of pol   in-
hibition in skin cancer was derived from the influence of 
the new substances and the known pol   and pol   in-
hibitor aphidicolin  [11] in normal and transformed hu-
man keratinocytes. Since therapeutic failure with nucleo-
side analogues can result from a lack of enzymatic ac-
tivation by kinases, degradation by phosphorylases or 
inducible drug transport out of the tumour cells, i.e., ke-
ratinocytes, the expression of relevant enzymes and 
transporters has to be taken into account, as well as the 
molecular weight and solubility of the agents. High mo-
lecular weight and poor solubility can seriously impair 
skin penetration and thus ask for adequate carrier sys-
tems to overcome the horny layer barrier.
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 Molecular Modelling Studies 
 Although crystal structures of several type B DNA 
polymerases are available [for a review on this field, see 
ref.  18, 19, 22 ], the three-dimensional structure of the hu-
man pol   had yet to be determined. Since a detailed 
three-dimensional model of the active site could facilitate 
the rational design of new inhibitors, a molecular model 
of the active site of pol   was constructed to study the 
structural requirements of pol   inhibition. The model 
for the tertiary structure of human pol   restricted to the 
836–1102 region  [20] contains, by analogy with other B 
family polymerases of known structures, the fingers, 
palm and thumb regions of the enzyme.
 Generation of the Active Site of Human pol   
 In the absence of experimental data, model building on 
the basis of the known three-dimensional structure of a 
homologous protein is at present the only reliable method 
to obtain structural information. For accurate structure 
prediction, this requires sequence identity of the target 
protein with templates of known structures of at least 30%. 
According to alignment results, the palm, fingers and 
thumb domains of human pol   share 34% identical resi-
dues and 49% similar residues with T9N7 polymerase, but 
only 20% identical and 28% similar with RB69 polymerase. 
Thus, T9N7 polymerase is the closer homologue, and 
should be a better choice for homology modelling. How-
ever, crystal coordinates were available only in the ‘apo’ 
(and therefore inactive) state, a conformation not useful 
for creating an active site model. Comparisons of the ter-
tiary structures of homologous proteins have shown that 
three-dimensional structures have been much better con-
served during evolution than protein primary structures. 
A close inspection of the three-dimensional crystal struc-
tures of the apo forms of T9N7 and RB69 polymerases in-
dicated an exact match of the active sites, despite their low 
sequence identity of about 17%. On the basis of these data, 
we concluded that RB69 polymerase seems to be a quite 
suitable template for modelling the pol   active site.
 The resulting architecture of our model is very similar 
to the crystal structure of RB69 polymerase, as can be 
seen in  figure 1 . The protein model was found to be stable, 
since restraints have not been necessary and the ternary 
complex with primer, template, deoxythymidine triphos-
phate (dTTP) and ions has remained fully intact during 
the molecular dynamics simulations. The dTTP binding 
site ( fig. 1 b) shows similar binding characteristics as seen 
in the crystal structure of RB69 polymerase: 3 conserved, 
positively charged residues, Arg922, Lys926, and Lys950 
form salt bridges with the   - and   -phosphate oxygens of 
the dTTP. The metal ions (Ca 2+ ions were taken accord-
Lys926
dTTP
Asp1004
Asp860
Arg922
Lys950
Tyr865
Ca
Ca
a b
 Fig. 1. Human DNA pol   model.  a Superposition of the protein 
backbones of the template (  -helices = red,   -sheets = yellow, 
loops = cyan) and the pol   model. The model contains the nucle-
otide binding domain only, consisting of a finger, palm and thumb 
region (  -helices = blue,   -sheets = green, loops = grey).  b A close-
up view of the dTTP binding complex. Hydrogen bonds are shown 
as black dashed lines. Colour code of the ligand: carbon = white, 
hydrogen = cyan, oxygen = red, nitrogen = blue, phosphorus = 
orange, calcium = green. From Richartz et al. [20] with permis-
sion (colour only in online version). 
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ing to the RB69 polymerase crystal structure) are ligated 
by Asp860 and Asp1004 and further complexed with the 
phosphate groups. Between the aromatic ring of Tyr865 
and the ribose of dTTP, a stacking interaction is formed 
accompanied by a hydrogen bond between the amide hy-
drogen of Tyr865 and the oxygen of the 3  -OH group of 
the ribose.
 Development of pol   Inhibitors by Molecular 
Modelling 
 Molecular dynamics simulations and docking of a se-
ries of known inhibitors were used to prove the active site 
model  [20] and to propose strategies for designing new 
inhibitors. Docking results of a series of known nucleo-
side analogue inhibitors are consistent with experimental 
data and offer the possibility to elucidate structure activ-
ity data on a molecular level. Furthermore, from these 
studies we can explain, at least partially, the effect of 
aphidicolin on pol   in vitro. In molecular dynamics sim-
ulations of the active site model, aphidicolin occupies the 
catalytic centre ( fig. 2 ), but acts in a not truly competitive 
manner with respect to nucleosides and nucleoside in-
hibitors, since it destabilizes the replicating ‘closed’ form 
and transfers the enzyme into the inactive ‘open’ confor-
mation.
 Docking of the natural substrate of pol   dTTP into 
the active site model revealed the formation of a hydrogen 
bond between the amide hydrogen of Tyr865 and the ox-
ygen of the 3  -OH group of the ribose ( fig. 1 b)  [20] . Con-
sequently, a carbonyl function instead of the hydroxyl 
group in position 3  (compound: HM-1-TP) would lead to 
an even better hydrogen bond acceptor, as illustrated in 
 figure 3 .
 Moreover, the binding mode of the known nucleotide 
analogue pol   inhibitor 2-butylanilino-dATP (BuP)  [20] 
suggested the possibility of an additional hydrogen bond 
formation with Tyr865. Thus, introduction of a hydroxyl 
group in ortho position to the butyl moiety of the butyl-
anilino group of BuP led to the new ligand BuP-OH-TP. 
The results of molecular dynamics simulations indicated 
the existence of a stable hydrogen bond of the OH group 
with Tyr865 ( fig. 3 b). A series of BuP-OH analogues in-
cluding those with non-linear side chain substituents 
(e.g. isohexyl side chain of the compound isoHex-OH) 
have been studied in detail with respect to their potential 
interaction geometries as well as affinities to the pol   
active site.
 In fact, molecular modelling studies also allowed a 
first step into the understanding of drug resistance mech-
anism for cytomegalovirus  [23] and HIV  [24] as well as 
the identification of new classes of HIV reverse transcrip-
tase inhibitors  [25, 26] . This shows the high potential of 
this rather new methodological approach, given that the 
identified agents prove to be active.
 Cytotoxic Activity 
 The thymidine analogue nucleoside HM-1 and the 
guanosine analogue BuP-OH as well as related agents 
were synthesized by Reissig and coworkers  [21] , Institute 
of Chemistry and Biochemistry, Freie Universität Berlin, 
and subjected to pharmacological screening in monolay-
er cultures of normal human keratinocytes (NHK)  [27] 
and transformed human keratinocytes (squamous cell 
carcinoma cell line SCC-25). Other than with molecular 
a b
 Fig. 2. The pol   /aphidicolin complex. The 
protein changes from the closed form (a) 
to the inactive open form (b) and the Ca 2+ 
ions move away from the catalytic centre. 
Colour code:   -helices = red,   -sheets = 
yellow, green, calcium ions = magenta, 
aphicolin = cyan. From Richartz et al. [20] 
with permission (colour only in online 
version). 
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modelling for which the triphosphates of the nucleoside 
analogues are necessary, cellular toxicity is investigated 
with the nucleoside analogues themselves. The triphos-
phates of the substances would be too hydrophilic to per-
meate the cell membrane and even more so the horny 
layer when applied topically.
 The phosphorylation of the substances is done intra-
cellularly by specific cellular kinases. To investigate if pol 
  inhibition may be an option for actinic keratosis and 
cutaneous squamous cell carcinoma therapy, the effects 
of the proposed compounds were compared to those of 
aphidicolin as well as to those of drugs approved for ac-
tinic keratosis (5-FU, diclofenac/hyaluronic acid) and the 
highly cytotoxic doxorubicin. The pyrophosphate ana-
logue foscarnet blocking the pyrophosphate binding site 
of viral pol   served as negative control, which in fact 
proved inactive  [21] .
 Inhibition of DNA Synthesis 
 As to be derived from thymidine incorporation, 
aphidicolin 10 –6  M – which was used for reference – com-
pletely inhibited DNA synthesis in NHK and the IC 50 val-
ue was in the submicromolar range. Yet SCC-25 cells were 
less sensitive with an IC 50 value in the micromolar range 
and a maximum inhibition of 57%. The higher toxicity 
for NHK than for the tumour cell line in fact explains the 
failure of aphidicolin in clinical testing. The proposed 
compound BuP-OH strongly inhibited the proliferation 
of normal keratinocytes as well. Yet other than with 
aphidicolin, SCC-25 cells were also strongly inhibited, 
toxic concentrations (–lg IC 50 ) of BuP-OH were close in 
NHK and SCC-25 cells, the purine derivative, however, 
was less potent than aphidicolin ( table 1 ). Nevertheless, 
BuP-OH may mean a clear step forward over aphidico-
lin.
 Besides aphidicolin, further reference substances were 
diclofenac used in the therapy of actinic keratosis and the 
cytotoxic agent doxorubicin. Causing 100% inhibition 
doxorubicin did not differentiate between NHK and 
SCC-25 cells. As to be expected, pronounced cytotoxic 
effects were also seen with doxorubicin. Diclofenac in-
hibited DNA synthesis in NHK and in SCC-25 cells at 
identical concentrations (–lg IC 50 about 4.3), but once 
more maximum inhibition in the tumour cell line was 
less than in normal keratinocytes. In mice, diclofenac 
failed to interfere with keratinocyte proliferation in a sur-
gical wound model  [28] while suppressing fibrosarcoma 
tumour growth  [29] .
 The inhibitory effect of 5-FU and HM-1 on keratino-
cyte proliferation was not tested with the thymidine up-
take assay. Exogenous thymidine probably antagonizes 
the thymidine analogues as well as the 5-FU-related de-
pletion of endogenous dTTP, and thus exerts an antipro-
liferative effect.
 Viability 
 Cell viability as determined by the MTT reduction test 
allowed to verify the data derived from the proliferation 
assay as well as to study 5-FU and HM-1 cytotoxicity.
5-FU was clearly less potent as compared to aphidicolin. 
DNA-Template Lys950
BuP-OH
Asp1004
Asp860
Tyr865
Val976
Leu960
Ala973
Tyr839
Lys926
Arg922Lys950
Asp1004
Asp860
Tyr865
HM-1
Ca
Ca
DNA-Template
a b
 Fig. 3. Docking of HM-1-TP ( a ) and BuP-OH-TP ( b ) into the active side of pol   : hydrogen bond formation of 
HM-1-TP and the high hydroxyl group in ortho position to the butyl moiety of BuP-OH-TP with Tyr865. For 
colour code of the ligand, see figure 1. From Höltje et al. [21] with permission (colour only in online version). 
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This holds true both with respect to –lg IC 50 and maxi-
mum inhibition of viability. A minor preference in toxic-
ity for transformed keratinocytes was detected ( table 1 ) 
which may be relevant in the patient. All proposed nucle-
osides appeared active, yet lacked the  potency of aphidi-
colin either with respect to both –lg IC 50 and maximum 
inhibition of viability (HM-1, isoHex-OH) or at least with 
respect to –lg IC 50 (BuP-OH). In fact, the maximum in-
hibitory capacity of aphidicolin is even superseded by 
BuP-OH regarding NHK and SCC-25 cells. Differences 
in the modelled nucleosides to 5-FU, however, were less 
obvious and maximum effects were even more pro-
nounced with BuP-OH. Most interestingly, a distinct se-
lectivity for SCC-25 cells was observed when studying 
HM-1 ( table 1 ). This agent appears particularly interest-
ing for clinical testing, though a compound both selective 
for the tumour cell and highly active (at least correspond-
ing to BuP-OH) should be of highest relevance.
 Taken together, new DNA pol   inhibitors were cre-
ated when applying molecular modelling methods. The 
nucleoside analogues are activated in transformed kera-
tinocytes, but also in normal keratinocytes. Activity of 
these substances ranked as follows: aphidicolin  1 BuP-
OH  1 5-FU  1 HM-1 when testing viability and ranked 
aphidicolin  1 1 BuP-OH when studying proliferation 
 [21] . The activation products appear to fit into the cata-
lytic domain of the target enzyme which is of very re-
stricted size  [20] . Thus, we were able to predict structures 
of DNA pol   inhibitors, and the order of activity in gen-
eral met our expectations. The model was predictive, giv-
en the ligands get unhindered access to the active site of 
the enzyme – which was not true for guanosine analogues 
having a non-linear substituent at the side chain (data not 
shown). The tumour cell specificity of HM-1, however, 
was not conceivable by molecular modelling. This selec-
tivity may be linked to differences in nucleotide metabo-
lism and transporters.
 Enzymes of Nucleotide Metabolism and Nucleotide 
Transporters 
 The expression of enzymes and outward transporters 
for relevant nucleosides and nucleotides has to be consid-
ered when aiming for nucleoside analogue drugs. The cy-
tosolic enzymes deoxycytidine kinase, thymidine kinase-
1 as well as the mitochondrial enzyme deoxyguanosine 
kinase were detected at the mRNA and protein level in 
NHK. This also holds true for the nucleoside inward 
transporter hENT-1 and the anionic outward transport-
ers MRP-4 and MRP-5  [21, 30] . The latter can cause nu-
cleoside resistance, if overexpressed. Moreover, NHK ex-
press the organic anion transporters OATP-B, OATP-D 
and OATP-E, which are involved in drug influx  [31] . 
SCC-25 cells hardly expressed the hENT-1 transporter as 
well as deoxycytidine kinase. For all other enzymes and 
transporters no relevant differences between normal ke-
ratinocytes and SCC-25 cells were seen  [21] . The differ-
ences in nucleotide transporter and enzyme expression, 
however, do not explain the NHK preference for the non-
nucleosidic aphidicolin nor the SCC-25 preference for the 
thymidine analogue HM-1.
 Skin Penetration 
 By the topical treatment of skin diseases the active 
pharmaceutical ingredient makes contact with the target 
site before entering the systemic circulation which – in 
general – is mandatory for contact with non-target sites. 
Therefore, systemic side effects are reduced as compared 
to parenteral or oral drug administration, which is of ma-
jor interest when applying drugs with limited tolerability 
as for example anticancer agents. Then surmounting the 
horny layer (stratum corneum) of the epidermis is the 
greatest challenge. To be well absorbed  [32] , a substance 
should have (1) a molecular mass less than 500 g/mol, (2) 
Table 1. –lg IC50 values (mean 8 SE) derived from thymidine in-
corporation and viability assay (MTT test)
Aphidicolin 5-FU HM-1 BuP-OH
Viability (48 h)
NHK 8.2680.41
(44)
5.0880.48
(41)
n.d.
(23)
4.5880.24
(66)
SCC-25 6.2980.29
(62)
6.0180.28
(42)
4.7480.34
(47)
5.0580.37
(65)
Proliferation (24 h)
NHK 7.0880.05
(100)
assay of [3H]thymidine in-
corporation not possible 
with thymidine analogues
5.5980.27
(100)
SCC-25 6.0780.18
(58)
5.0780.38
(87)
Reduction was calculated after non-linear regression as
100 – E. E = Activity at 10–4 M in percent (see figures in parenthe-
ses); n.d. = lg IC50 is not determinable with maximum inhibition 
≤30% (from Höltje et al. [21]).
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a low melting point, (3) adequate solubility in oil and wa-
ter, and (4) an octanol:water partition coefficient (logP) 
of about 1 to 3.
 If this does not hold true for a drug molecule or if the 
parameters are close to the limits (e.g. calculated logP of 
HM-1 –1.13; molecular mass of BuP-OH 414.47), colloi-
dal carrier systems widely varying in structure can be 
used  [32] . Whereas in the early days research in drug car-
rier systems focussed on liposomes, this today also in-
volves the more stable solid lipid nanoparticles (SLN) 
made up from lipids solid at room temperature and nano-
structured lipidic carriers built up from lipid mixtures 
solid and fluid at room temperature [for a review, see ref. 
 33 ]. These particles of about 200 nm in diameter stabi-
lized by surfactants gained more and more interest over 
time not only for parenteral and oral use, but also for 
topical application on the skin.
0
50
100
Stratum corneum Epidermis Dermis
150
200
250
A
BU
 Fig. 4. Effects of nanoparticle size on dye 
penetration into pig skin: arbitrary pixel 
brightness values (ABU) following the ap-
plication of lipid nanocapsules 60 (black 
columns), 90 (grey columns), and 185 nm 
(white columns) in diameter loaded with 
0.004% nile red (n = 3). From Küchler et al. 
[38] with permission. 
a b c
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6,000
Stratum corneum Epidermis Dermis
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 Fig. 5. Staining of pig skin following the 
application of 0.004% nile red-loaded 
cream ( a ), SLN ( b ) and CMS nanotrans-
porters ( c ). The pictures are obtained by 
superposing normal light and fluores-
cence images of the same area.  d The
arbitrary pixel brightness values (ABU) 
corrected for background fluorescence 
(cream = black columns; SLN = grey col-
umns; CMS nanotransporters = white
columns). The inserted numbers give the 
respective enhancement of penetration 
over cream. The asterisk indicates signifi-
cant differences (p  ^  0.05). From Küchler 
et al. [37] with permission. 
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 Detailed investigations into various lipidic systems 
(SLN, nanostructured lipidic carriers, nano-emulsions, 
lipid microparticles, nanocapsules) proved SLN to be 
most effective enhancing skin penetration 4-fold to 8-
fold over a cream used for reference  [34–37] . Loadable are 
not only lipophilic agents such as steroids or the model 
dye nile red, but also hydrophilic agents – which are then 
located in the polymer shell and thus increase particle 
size considerably  [38] . The size of particles ranging from 
50 to 200 nm in diameter for skin penetration of the load-
ed compound appeared less relevant ( fig. 4 )  [38] . The im-
proved delivery by SLN results from mixing of the car-
rier lipid and skin surface lipids  [37] . It is tempting to 
speculate that skin occlusion may add to the improved 
uptake  [33] .
 Core-multishell (CMS) nanotransporters may be even 
more efficient. These improved (surface-modified) den-
drimers were first described by Haag and Kratz  [39] and 
Quadir et al.  [40] . The primary aim was the design of pH-
responsive carriers for the targeting of tumour cells  [41] . 
CMS nanotransporters can enhance the skin penetration 
of lipophilic agents even 8- to 13-fold ( fig. 5 )  [37] .
 To be suitable for pharmaceutical use, the application 
system has to be well tolerated. Whereas this can be a ma-
jor problem with charged particles including dendrimers 
built up from a propylene amine core and lipid particles 
containing for example cetyl amine as a matrix compo-
nent  [42–47] , SLN and CMS nanotransporters are well 
tolerated by keratinocyte monolayer cultures as well as 
reconstructed human epidermis  [34, 48, 49] and thus 
may be suitable delivery systems for the nucleoside ana-
logue pol   inhibitors. Therefore, the results of further 
preclinical and clinical testing should well prove reward-
ing.
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